Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Prenetics lifts projected second-half loss to $30-35M, betting on IM8 growth

The Nasdaq-listed group more than triples its expected adjusted EBITDA loss to fund customer acquisition for IM8, while holding its full-year revenue range.

18 Nov 2026 · Prenetics Global Ltd PRE · Company news

Prenetics Global is accepting a much deeper near-term loss to push its IM8 supplement brand. In its third-quarter 2026 shareholder letter, the company said it now expects an adjusted EBITDA loss of $30-35 million for the second half of the year. Its earlier range was $8-12 million, so the projected loss is about $22-23 million wider at both ends. Prenetics attributed the change to a decision to spend more on acquiring IM8 customers.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Prenetics Global Ltd ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →